Evaluation of the Dutch neonatal screening for congenital adrenal hyperplasia

Background In 2002, a nationwide screening for congenital adrenal hyperplasia (CAH) was introduced in the Netherlands. The aim of our study is to evaluate the validity of the neonatal screening for CAH and to assess how many newborns with salt-wasting (SW) CAH have already been clinically diagnosed before the screening result was known. Methods Retrospective, descriptive study. The following data of patients with positive screening results since implementation of the screening programme were collected (1 January 2002 up until 31 December 2013): gestational age, sex, diagnosis, clinical presentation and contribution of screening to the diagnosis. Results In the evaluated period, 2 235 931 newborns were screened. 479 children had an abnormal screening result, 133 children were diagnosed with CAH (114 SW, 14 simple virilizing (SV)), five non-classic CAH. During this period, no patients with SW CAH were missed by neonatal screening (sensitivity was 100%). After exclusion of 17 cases with missing information on diagnosis, specificity was 99.98% and positive predictive value was 24.7%. Most false positives (30%) were attributable to prematurity. Of patients with SW CAH, 68% (71/104) patients were detected by neonatal screening and 33 (33/104) were clinically diagnosed. Of girls with SW CAH, 38% (14/37) were detected by neonatal screening and 62% (23/37) were clinically diagnosed. Conclusion The Dutch neonatal screening has an excellent sensitivity and high specificity. Both boys and girls can benefit from neonatal screening.

[1]  V. Anandi,et al.  Evaluation of factors associated with elevated newborn 17-hydroxyprogesterone levels , 2017, Journal of pediatric endocrinology & metabolism : JPEM.

[2]  B. Mendonca,et al.  Neonatal 17‐hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening , 2017, Clinical endocrinology.

[3]  E. Endert,et al.  Determination of a steroid profile in heel prick blood using LC-MS/MS. , 2016, Bioanalysis.

[4]  T. Morio,et al.  Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study , 2015, BMC Pediatrics.

[5]  W. H. Hannon,et al.  Congenital adrenal hyperplasia cases identified by newborn screening in one- and two-screen states. , 2015, Molecular genetics and metabolism.

[6]  C. Bereczki,et al.  Concurrent Confirmation and Differential Diagnosis of Congenital Adrenal Hyperplasia from Dried Blood Spots: Application of a Second-Tier LC-MS/MS Assay in a Cross-Border Cooperation for Newborn Screening , 2015, Hormone Research in Paediatrics.

[7]  Yannan Jiang,et al.  Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013. , 2015, The Journal of clinical endocrinology and metabolism.

[8]  A. Lofrano-Porto,et al.  3β-hydroxysteroid dehydrogenase type II deficiency on newborn screening test. , 2014, Arquivos brasileiros de endocrinologia e metabologia.

[9]  A. Nordenström,et al.  Nationwide neonatal screening for congenital adrenal hyperplasia in sweden: a 26-year longitudinal prospective population-based study. , 2014, JAMA pediatrics.

[10]  M. Hartmann,et al.  Reduced activity of 11β-hydroxylase accounts for elevated 17α-hydroxyprogesterone in preterms. , 2014, The Journal of pediatrics.

[11]  W. Thomas,et al.  Comparison of newborn screening protocols for congenital adrenal hyperplasia in preterm infants. , 2014, The Journal of pediatrics.

[12]  I. Silva,et al.  A three-year follow-up of congenital adrenal hyperplasia newborn screening. , 2014, Jornal de pediatria.

[13]  P. Clayton,et al.  No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening , 2013, Archives of Disease in Childhood.

[14]  P. Hindmarsh,et al.  Late clinical presentation of congenital adrenal hyperplasia in older children: findings from national paediatric surveillance , 2013, Archives of Disease in Childhood.

[15]  K. McFann,et al.  Congenital adrenal hyperplasia and the second newborn screen. , 2013, The Journal of pediatrics.

[16]  J. Fernández,et al.  Newborn screening for congenital adrenal hyperplasia in Cuba: six years of experience. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[17]  T. Yuen,et al.  Genotype–phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency , 2013, Proceedings of the National Academy of Sciences.

[18]  I. Silva,et al.  Neonatal screening for congenital adrenal hyperplasia. , 2012, Revista da Associacao Medica Brasileira.

[19]  K. Allegaert,et al.  RISK FACTORS FOR ELEVATED LEVELS OF 17-HYDROXYPROGESTERONE DURING NEONATAL INTENSIVE CARE UNIT ADMISSION , 2012, Acta clinica Belgica.

[20]  J. Coste,et al.  Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. , 2012, Archives of pediatrics & adolescent medicine.

[21]  M. Dattani,et al.  Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency , 2011, The Journal of clinical endocrinology and metabolism.

[22]  M. Irie,et al.  Neonatal Screening for Congenital Adrenal Hyperplasia in Japan , 1985, Annals of the New York Academy of Sciences.

[23]  D. Matern,et al.  Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance , 2012, European Journal of Pediatrics.

[24]  P. White.  Neonatal screening for congenital adrenal hyperplasia , 2009, Nature Reviews Endocrinology.

[25]  R. Hopkin,et al.  Cytochrome P450 Oxidoreductase Deficiency , 2009 .

[26]  N. Krone,et al.  Genetics of congenital adrenal hyperplasia. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[27]  M. Lee,et al.  Corrected 17-alpha-hydroxyprogesterone values adjusted by a scoring system for screening congenital adrenal hyperplasia in premature infants. , 2008, Annals of clinical and laboratory science.

[28]  M. Peter,et al.  A Case of 11β-Hydroxylase Deficiency Detected in a Newborn Screening Program by Second-Tier LC-MS/MS , 2008, Hormone Research in Paediatrics.

[29]  U. Steuerwald,et al.  Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. , 2007, The Journal of clinical endocrinology and metabolism.

[30]  S. Grosse,et al.  How Many Deaths Can Be Prevented by Newborn Screening for Congenital Adrenal Hyperplasia? , 2007, Hormone Research in Paediatrics.

[31]  J. Wit,et al.  Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. , 2005, The Journal of clinical endocrinology and metabolism.

[32]  J. Popović,et al.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2005, Journal for specialists in pediatric nursing : JSPN.

[33]  J. Wit,et al.  Neonatal screening for congenital adrenal hyperplasia. , 2004, European journal of endocrinology.

[34]  P. Czernichow,et al.  Screening for neonatal endocrinopathies: rationale, methods and results. , 2004, Seminars in neonatology : SN.

[35]  P. White,et al.  Congenital Adrenal Hyperplasia , 1964, The Lancet.

[36]  C. Noordam,et al.  Newborn screening for congenital adrenal hyperplasia in the Netherlands. , 2001, Pediatrics.

[37]  G. Heinze,et al.  Lessons from 30 years of clinical diagnosis and treatment of congenital adrenal hyperplasia in five middle European countries. , 2001, The Journal of clinical endocrinology and metabolism.

[38]  S. Berenbaum,et al.  Results of Screening 1.9 Million Texas Newborns for 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia , 1998, Pediatrics.

[39]  A. Nordenström,et al.  Benefits of Neonatal Screening for Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) in Sweden , 1998, Pediatrics.

[40]  M. New,et al.  Congenital adrenal hyperplasia. , 1988, Biochemical Society transactions.